Spider venom drug heads to clinical trial to reverse heart attack damage
SMRTR summary
A new drug derived from spider venom could protect hearts during heart attacks and improve donor heart viability. Australian researchers are preparing for human trials of the synthetic Hi1a peptide, which blocks acid-sensing channels in heart cells to prevent tissue damage from oxygen deprivation. The $17.8 million study aims to reduce heart attack deaths and expand the donor heart pool.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article